ITT Inc
Change company Symbol lookup
Select an option...
ITT ITT Inc
PLBY Plby Group Inc
SVFA SVF Investment Corp
ROIUF Route1 Inc
MPB Mid Penn Bancorp Inc
NWSA News Corp
BAC Bank of America Corp
BA Boeing Co
EGRNF China Evergrande Group
SHYF Shyft Group Inc
Go

Industrials : Machinery | Mid Cap Blend
Company profile

ITT Inc. is a manufacturer of engineered critical components and customized technology solutions for the energy, transportation and industrial markets. The Company operates through four segments. The Industrial Process (IP) segment is an original equipment manufacturer and service provider offering a range of industrial pumps, valves and plant optimization systems and services. The Motion Technologies (MT) segment is a manufacturer of braking pads, shims, shock absorbers, damping, and sealing technologies for the transportation industry, including passenger cars, buses, and rail transportation. The Interconnect Solutions (ICS) segment designs and manufactures engineered connectors and cable assemblies for a range of applications in a range of environments. The Control Technologies (CT) segment manufactures equipment, including actuation, fuel management, noise and energy absorption, and environmental control system components, for the aerospace and defense, and industrial markets.

Closing Price
$87.41
Day's Change
-1.61 (-1.81%)
Bid
--
Ask
--
B/A Size
--
Day's High
88.89
Day's Low
86.82
Volume
(Heavy Day)
Volume:
1,254,778

10-day average volume:
528,236
1,254,778

aTyr Pharma Announces Second Quarter 2021 Results and Provides Corporate Update

4:00 pm ET August 10, 2021 (Globe Newswire) Print

Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in mid-September 2021.

Company to host conference call and webcast today, August 10th, at 5:00 p.m. EDT / 2:00 p.m. PDT.

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced second quarter 2021 results and provided a corporate update.

"We recently completed the last subject visit in our Phase 1b/2a proof-of-concept study of our lead therapeutic candidate, ATYR1923, in pulmonary sarcoidosis, our initial interstitial lung disease (ILD) indication. We expect to report results from this important study in mid-September 2021," said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. "This is a significant milestone for aTyr and the sarcoidosis community, and the upcoming readout represents a key inflection point for our ATYR1923 clinical program and tRNA synthetase biology platform."

"The clinical proof-of-mechanism for ATYR1923 established in our Phase 2 study in COVID-19 patients and the favorable clinical safety profile demonstrated to date, along with the pre-clinical efficacy observed in multiple translational ILD models, support the potential for ATYR1923 as a new therapeutic approach for patients with pulmonary sarcoidosis and possibly other forms of ILD. We believe ATYR1923 could potentially offer an alternative to current treatments such as steroids with improved efficacy and fewer side effects."

Second Quarter 2021 and Subsequent Period Highlights

Second Quarter 2021 Financial Highlights

Conference Call and Webcast Details

aTyr will host a conference call and webcast today at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to discuss its financial results and provide a corporate update. Interested parties may access the call by dialing toll-free 844-358-9116 from the US, or 209-905-5951 internationally and using conference ID 4692110. Links to a live audio webcast and replay may be accessed on the aTyr website events page at: http://investors.atyrpharma.com/events-and-webcasts. An audio replay will be available for at least 90 days following the event.

About ATYR1923

aTyr is developing ATYR1923 as a potential therapeutic for patients with inflammatory lung disease. ATYR1923, a fusion protein comprised of the immuno-modulatory domain of histidyl tRNA synthetase fused to the FC region of a human antibody, is a selective modulator of Neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory disease states. aTyr has completed enrollment in a proof-of-concept Phase 1b/2a trial evaluating ATYR1923 in patients with pulmonary sarcoidosis. This Phase 1b/2a study is a multi-ascending dose, placebo-controlled, first-in-patient study of ATYR1923 that has been designed to evaluate the safety, tolerability, steroid sparing effect, immunogenicity and pharmacokinetics profile of multiple doses of ATYR1923. Proof-of-mechanism for ATYR1923 was established in a Phase 2 clinical trial in COVID-19 patients with severe respiratory complications, which demonstrated that ATYR1923 reduced inflammatory cytokine levels in patients consistent with preclinical models, including cytokines that are implicated in sarcoidosis and other forms of interstitial lung disease.

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr's research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr's primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include statements regarding the potential therapeutic benefits and applications of ATYR1923, ATYR2810 and our discovery programs; timelines and plans with respect to certain development activities (including the further development of ATYR9123, ATYR2810 and our discovery programs and the timing of data from clinical trials) and value to be derived therefrom; expected activities under our collaboration agreements and certain development goals. These forward-looking statements also reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects, as reflected in or suggested by these forward-looking statements, are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. Furthermore, actual results may differ materially from those described in these forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, the fact that NRP2 and tRNA synthetase biology is not fully understood, uncertainty regarding the COVID-19 pandemic, including the risk of delays in enrollment in our clinical trials, risks associated with the discovery, development and regulation of our product candidates, including the risk that results from clinical trials or other studies may not support further development, the risk that we may cease or delay preclinical or clinical development activities for any of our existing or future product candidates for a variety of reasons, the fact that our collaboration agreements are subject to early termination, and the risk that we may not be able to raise the additional funding required for our business and product development plans, as well as those risks set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and in our other SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

ATYR PHARMA INC.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
                                                                             Three Months Ended                    Six Months Ended
                                                                             June 30,                              June 30,
                                                                             2021                2020              2021              2020
                                                                             (unaudited)
Revenues:
License and collaboration agreement revenues                                 $   --              $   189           $  --             $  8,254
Total revenues                                                                   --                  189              --                8,254
Operating expenses:
Research and development                                                         7,655               4,361            12,171            7,977
General and administrative                                                       2,790               2,146            5,476             4,736
Total operating expenses                                                         10,445              6,507            17,647            12,713
Loss from operations                                                             (10,445    )        (6,318    )      (17,647    )      (4,459    )
Total other income (expense), net                                                53                  (129      )      100               (236      )
Consolidated net loss                                                        $   (10,392    )    $   (6,447    )   $  (17,547    )   $  (4,695    )
Net loss attributable to noncontrolling interest in Pangu BioPharma Limited      1                   1                5                 2
Net loss attributable to aTyr Pharma, Inc.                                   $   (10,391    )    $   (6,446    )   $  (17,542    )   $  (4,693    )
Net loss per share, basic and diluted                                        $   (0.64      )    $   (0.69     )   $  (1.16      )   $  (0.58     )
Shares used in computing basic net loss per share, basic and diluted             16,128,473          9,357,432        15,121,721        8,119,612
ATYR PHARMA INC.
Condensed Consolidated Balance Sheets
(in thousands)
                                                                       June 30,       December 31,
                                                                       2021           2020
                                                                       (unaudited)
Cash, cash equivalents and available-for-sale investments, short-term  $     44,061   $      31,689
Other receivables                                                            90              2,039
Property and equipment, net                                                  751             899
Right-of-use assets                                                          1,685           2,083
Prepaid expenses and other assets                                            2,408           2,016
Total assets                                                           $     48,995   $      38,726
Accounts payable, accrued expenses and other liabilities               $     6,365    $      5,003
Current portion of operating lease liability                                 919             861
Long-term operating lease liability, net of current portion                  906             1,378
Total stockholders' equity                                                   40,805          31,484
Total liabilities and stockholders' equity                             $     48,995   $      38,726
Contact:
Ashlee Dunston
Director, Investor Relations and Corporate Communications
adunston@atyrpharma.com

https://ml.globenewswire.com/media/d9b4b478-f8bd-4014-91ed-429caab67931/small/atyr-logo-png.png

https://ml.globenewswire.com/media/d9b4b478-f8bd-4014-91ed-429caab67931/small/atyr-logo-png.png

comtex tracking

COMTEX_391338395/2010/2021-08-10T16:00:02

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.